Herantis Pharma - Funded to key data inflection points
Herantis Pharma is focused on the development of innovative regenerative medicines targeting unmet needs. The recent virtual capital markets day highlighted the progress of its two innovative assets: cerebral dopamine neurotrophic factor (CDNF), a potential disease-modifying treatment for Parkinson’s disease (PD); and Lymfactin, the only gene therapy in development for breast cancer-associated lymphedema (BCAL). Top-line data from the first part of the Phase I/II CDNF trial confirmed its safety in PD and encouragingly, early biological efficacy signals (PET imaging) of its neurorestorative effects. Lymfactin (AdeLE) data are expected in Q121. Herantis is funded into 2021 key inflection points and expects little impact from COVID-19 in the near term. We value Herantis at €87.2m.Herantis Pharma Oyj. Herantis Pharma Oyj is a Finland-based pharmaceutical company. It is engaged in the development of treatments for unmet clinical needs, such as dry eye syndrome, Parkinson's disease and secondary lymphedema, among others. The Company's product development portfolio includes: Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfaticin aimed at secondary lymphedema, Cis-UCA emulsion cream for atopis dermatitis, and CDNF targeting Amyotrophic Lateral Sclerosis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.